^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Leiomyosarcoma |
| Drug: | doxorubicin hydrochloride (Topoisomerase II inhibitor) + dacarbazine (DNA synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
03/29/2022
Excerpt:
Soft Tissue Sarcoma...Other Recommended Regimens...AD LMS only (doxorubicin, dacarbazine) - if ifosfamide is not considered appropriate
